Dato-DXd

T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

by
T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe

Trastuzumab deruxtecan ( T-DXd , DS-8201 ) has a clinical incidence of interstitial lung disease (ILD) of approximately 10-15%. The mechanism of occurrence is not due to a single factor, but rather an interaction between target-dependent and non-target-dependent pathways. Firstly, the target-dependent mechanism arises from the low expression levels of HER2 in alveolar epithelial cells … Read more

A New Chapter in ESMO: Professor Yang Qingmo Analyzes Innovations in ADC Drug Therapy, Opening New Horizons for HR+ MBC Treatment

by
A New Chapter in ESMO: Professor Yang Qingmo Analyzes Innovations in ADC Drug Therapy, Opening New Horizons for HR+ MBC Treatment

*For reference by medical professionals only ADC drugs reshape the stratified treatment strategy for HR+ advanced breast cancer In recent years, the rapid development of antibody-drug conjugates (ADC) has brought groundbreaking progress to the treatment of advanced breast cancer.Trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd) are representative drugs that are profoundly changing the treatment landscape … Read more